These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29405254)

  • 1. Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
    Br J Dermatol; 2018 Jul; 179(1):213-215. PubMed ID: 29405254
    [No Abstract]   [Full Text] [Related]  

  • 2. MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma.
    Nakahara S; Fukushima S; Okada E; Morinaga J; Kubo Y; Tokuzumi A; Matsumoto S; Tsuruta-Kadohisa M; Kimura T; Kuriyama H; Miyashita A; Kajihara I; Jinnin M; Ihn H
    J Dermatol Sci; 2020 Jan; 97(1):77-79. PubMed ID: 31843231
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
    Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
    Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of neutrophil to lymphocyte ratio in advanced melanoma treated with anti-programmed death-1 therapy.
    Minowa T; Kato J; Hida T; Horimoto K; Sato S; Sawada M; Uhara H
    J Dermatol; 2018 Sep; 45(9):e250-e251. PubMed ID: 29572922
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
    Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
    J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients.
    Omodaka T; Minagawa A; Uhara H; Wakamatsu K; Koizumi T; Yokokawa Y; Koga H; Okuyama R
    J Dermatol; 2018 Nov; 45(11):1340-1344. PubMed ID: 30144152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma.
    Ohashi H; Takeuchi S; Miyagaki T; Kadono T
    Drug Discov Ther; 2020 Jul; 14(3):117-121. PubMed ID: 32595179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
    Stein JE; Soni A; Danilova L; Cottrell TR; Gajewski TF; Hodi FS; Bhatia S; Urba WJ; Sharfman WH; Wind-Rotolo M; Edwards R; Lipson EJ; Taube JM
    Ann Oncol; 2019 Apr; 30(4):589-596. PubMed ID: 30689736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.
    Sundahl N; Seremet T; Van Dorpe J; Neyns B; Ferdinande L; Meireson A; Brochez L; Kruse V; Ost P
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):828-835. PubMed ID: 30951807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy toxicity predicted by circulating cytokines.
    Gourd E
    Lancet Oncol; 2018 Dec; 19(12):e676. PubMed ID: 30449658
    [No Abstract]   [Full Text] [Related]  

  • 12. Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
    Balatoni T; Ladányi A; Fröhlich G; Czirbesz K; Kovács P; Pánczél G; Bence E; Plótár V; Liszkay G
    Pathol Oncol Res; 2020 Jan; 26(1):317-325. PubMed ID: 30225783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
    Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
    BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Machine-Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma.
    Wang R; Shao X; Zheng J; Saci A; Qian X; Pak I; Roy A; Bello A; Rizzo JI; Hosein F; Moss RA; Wind-Rotolo M; Feng Y
    Clin Pharmacol Ther; 2020 Apr; 107(4):978-987. PubMed ID: 31721173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
    Kasanen H; Hernberg M; Mäkelä S; Brück O; Juteau S; Kohtamäki L; Ilander M; Mustjoki S; Kreutzman A
    Cancer Immunol Immunother; 2020 May; 69(5):717-730. PubMed ID: 32036449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.
    Postow MA; Chasalow SD; Kuk D; Panageas KS; Cheng ML; Yuan J; Wolchok JD
    Melanoma Res; 2020 Feb; 30(1):71-75. PubMed ID: 31425479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Gosho M; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
    J Dermatol Sci; 2017 Nov; 88(2):225-231. PubMed ID: 28736218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study.
    Namikawa K; Takahashi A; Mori T; Tsutsumida A; Suzuki S; Motoi N; Jinnai S; Kage Y; Mizuta H; Muto Y; Nakano E; Yamazaki N
    Melanoma Res; 2020 Feb; 30(1):76-84. PubMed ID: 31095037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting marker for early progression in unresectable melanoma treated with nivolumab.
    Kondo T; Nomura M; Otsuka A; Nonomura Y; Kaku Y; Matsumoto S; Muto M
    Int J Clin Oncol; 2019 Mar; 24(3):323-327. PubMed ID: 30168088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?
    Quéreux G; Wylomanski S; Bouquin R; Saint-Jean M; Peuvrel L; Knol AC; Hanf M; Dréno B
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e39-e40. PubMed ID: 28750150
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.